By screening 46 biomarkers associated with cancer proliferation, drug-resistance, and metastasis, i.e., genes closely associated to patient overall survival, they proposed a risk score with high prognostic value based on the expression of five genes: MET (MET proto-oncogene and receptor tyrosine kinase), CPM (carboxypeptidase M), SHMT2 (serine hydroxymethyltransferase 2), GUCA2B (guanylate cyclase activator 2B), and SCN9A. MET and SHMT2 were upregulated whereas CPM, GUCA2B, and SCN9A were downregulated. This evidence concerns the gene SHMT2 and cancer.